NCT05824468 2026-03-10Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical CancerSun Yat-sen UniversityPhase 2 Active not recruiting30 enrolled
NCT03860272 2025-02-06Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled